Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites

Drug Metabolism and Disposition

Volumn 33, Issue 6, 2005, Pages 771-777

  Pekol, Teresa ^a   Daniels, J Scott ^a   Labutti, Jason ^a   Parsons, Ian ^a   Nix, Darrell ^a   Baronas, Elizabeth ^a   Hsieh, Frank ^a   Gan, Liang Shang ^a   Miwa, Gerald ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYL 2 [(PYRAZINE 2 CARBONYL)AMINO]PROPIONIC ACID; BORTEZOMIB; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; LEUCINE; PHENYLALANINE; PYRAZINE 2 CARBOXYLIC ACID (1 CARBAMOYL 2 PHENYLETHYL)AMIDE; PYRAZINE 2 CARBOXYLIC ACID [1 (1 HYDROXY 3 METHYLBUTYLCARBAMOYL) 2 PHENYL ETHYL]AMIDE; PYRAZINE 2 CARBOXYLIC ACID [1 BENZYL 2 (3 METHYLBUTYRYLAMINO) 2 OXOETHYL]AMIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DIASTEREOISOMER; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

BORONIC ACIDS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 18844383217     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002956     Document Type: Article

References (29)

1. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma Y-T, Plamondon L, and Stein RL (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333-338.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, and Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622.
3. Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, and Lin JH (1996) Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 24:1389-1394.
4. Bold RJ, Virudachalam S, and McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11-17.
5. Brot E, Haney BP, Hu K, Chiavelli C, Pickersgill IF, Bishop J, Parsons I, Lu Q, and Huang R (2003) Oxidative degradation of VELCADE, in Abstracts, 31st Northeast Regional Meeting of the American Chemical Society; 2003 June 15-18; Saratoga Springs, NY. pp 10.
6. Brown HC, Midland MM, and Kabalka GW (1971) Stoichiometrically controlled reaction of organoboranes with oxygen under very mild conditions to achieve essentially quantitative conversion into alcohols. J Am Chem Soc 93:1024-1025.
7. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, and Baldwin AS Jr (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res 61:3535-3540.
8. Dahlmann B, Kopp F, Kuehn L, Niedel B, Pfeifer G, Hegerl R, and Baumeister W (1989) The multicatalytic proteinase (prosome) is ubiquitous from eukaryotes to archaebacteria. FEBS Lett 251:125-131.
9. Daniels JS, Labutti J, Chavan A, Huang R, Parsons I, Gan L-S, and Miwa G (2003) Mechanistic investigations into the protein and glutathione mediated deboronation of the novel peptide boronic acid proteasome inhibitor bortezomib (VELCADE). Drug Metab Rev 35:44.
10. Fisher MB, Thompson SJ, Ribeiro V, Lechner MC, and Rettie AE (1998) P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of D3-valproic acid generated by baculovirus-expressed CYP3A1. Arch Biochem Biophys 356:63-70.
11. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, and Anderson KC (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534.
12. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
13. Hussain MA, Knabb R, Aungst BJ, and Kettner C (1991) Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats. Peptides 12:1153-1154.
14. Kelly TA, Adams J, Bachovchin WW, Barton RW, Campbell SJ, Coutts SJ, Kennedy CA, and Snow RJ (1993) Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. J Am Chem Soc 115:12637-12638.
15. Kettner CA and Shenvi AB (1984) Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G and chymotrypsin by peptide boronic acids. J Biol Chem 259:15106-15114.
16. London RE and Gabel SA (2001) Development and evaluation of a boronate inhibitor of g-glutamyl transpeptidase. Arch Biochem Biophys 385:250-258.
17. Lupas A, Koster AJ, and Baumeister W (1994) Structural features of 26S and 20S proteasomes. Enzyme Protein 47:252-273.
18. McCormack T, Baumeister W, Grenier L, Moomaw C, Plamondon L, Pramanik B, Slaughter C, Soucy F, Stein R, Zuhl F, and Dick L (1997) Active site-directed inhibitors of Rhodococcus 20 S proteasome. Kinetics and mechanism. J Biol Chem 272:26103-26109.
19. Mirviss SB (1967) Mechanism of the oxidation of trialkylboranes. J Org Chem 32:1713-1717.
20. Morgan EW, Yan B, Greenway D, Petersen DR, and Parkinson A (1994) Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). Arch Biochem Biophys 315:495-512.
21. Priestley ES and Decicco CP (2000) 1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease. Org Lett 2:3095-3097.
22. Rettie AE, Boberg M, Rettenmeier AW, and Baillie TA (1988) Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects and mechanistic studies. J Biol Chem 263:13733-13738.
23. Rettie AE, Rettenmeier AW, Howald WN, and Baillie TA (1987) Cytochrome P-450-catalyzed formation of D4-VPA, a toxic metabolite of valproic acid. Science (Wash DC) 235:890-893.
24. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
25. Satoh T and Hosokawa M (1998) The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 38:257-288.
26. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, and Callery MP (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-122.
27. Uttamsingh V, Lu C, Labutti J, Daniels JS, Huang R, Gan L-S, and Miwa G (2003) Relative contribution of CYP isoforms to the liver microsomal intrinsic clearance of bortezomib (VELCADE) in humans. Drug Metab Rev 35:184.
28. Wu S, Waugh W, and Stella VJ (2000) Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)2. J Pharm Sci 89:758-765.
29. Yang W, Gao X, and Wang B (2003) Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 23:346-368.